Entera Bio (NASDAQ: ENTX) and OPKO Health (NASDAQ: OPK) Report Positive Results on Novel Oral Treatment for Obesity and Metabolic Disorders
In a recent announcement, H.C. Wainwright reiterated a Buy rating on Entera Bio with a price target of $10.00 in light of their collaboration with OPKO Health. The research conducted by the two companies revealed positive top-line results on a novel oral treatment for obesity and metabolic disorders.
The joint research focused on combining OPKO's long-acting oxyntomodulin (OXM) analog with Entera's N-Tab technology to create the first oral dual agonist GLP-1/glucagon peptide. This potential once-daily treatment aims to address obesity, metabolic, and fibrotic disorders by leveraging OXM's appetite suppression and weight loss induction properties.
Successful in vivo proof-of-concept pharmacokinetic and pharmacodynamic studies using rodent and pig models demonstrated significant systemic exposure to oral OXM after a single dose. These findings have reinforced H.C. Wainwright's positive outlook on Entera Bio's stock, maintaining the Buy rating and the 12-month price target.
Furthermore, recent news highlighted positive preliminary results from the joint research, showcasing the favorable pharmacokinetic profile of the oral OXM after a single dose. The study also indicated promising glucose tolerance test results in rats, supporting the continued development of the treatment.
In addition to these advancements, Entera Bio's shareholders approved key proposals, including new members to the Board of Directors and revised compensation terms. These developments mark significant progress in the treatment of obesity and related disorders.
In conclusion, the collaboration between Entera Bio and OPKO Health holds great promise for the future of oral therapies for obesity and metabolic disorders. Investors and individuals looking to address these health concerns should keep a close eye on the progress of this innovative research.
